Form 8-K - Current report:
SEC Accession No. 0001104659-21-139005
Filing Date
2021-11-15
Accepted
2021-11-15 14:33:24
Documents
14
Period of Report
2021-11-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2132744d2_8k.htm   iXBRL 8-K 28904
2 EXHIBIT 99.1 tm2132744d2_ex99-1.htm EX-99.1 7210
6 GRAPHIC tm2132744d2_ex99-1img01.jpg GRAPHIC 3479
  Complete submission text file 0001104659-21-139005.txt   220395

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20211115.xsd EX-101.SCH 3195
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20211115_lab.xml EX-101.LAB 34594
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20211115_pre.xml EX-101.PRE 22717
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2132744d2_8k_htm.xml XML 3715
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 211409250
SIC: 2834 Pharmaceutical Preparations